Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;55(1):1228-1233.
doi: 10.1080/13880209.2017.1296000.

Evaluation of genotoxic effects of 3-methyl-5-(4-carboxycyclohexylmethyl)-tetrahydro-2H-1,3,5-thiadiazine-2-thione on human peripheral lymphocytes

Ece Avuloğlu-Yılmaz  1 , Deniz Yüzbaşıoğlu  1 , Azime Berna Özçelik  2 , Seyhan Ersan  2 , Fatma Ünal  1
Affiliations

Evaluation of genotoxic effects of 3-methyl-5-(4-carboxycyclohexylmethyl)-tetrahydro-2H-1,3,5-thiadiazine-2-thione on human peripheral lymphocytes

Ece Avuloğlu-Yılmaz et al. Pharm Biol. 2017 Dec.

Abstract

Context: Tranexamic acid is commonly used for curing abnormal bleeding in a variety of diseases. In a previous study, 12 different tetrahydro-2H-1,3,5-thiadiazine derivatives were synthesized from the amine group of tranexamic acid. Their antifibrinolytic and antimicrobial activities were compared with tranexamic acid. 3-Methyl-5-(4-carboxycyclohexylmethyl)-tetrahydro-2H-1,3,5-thiadiazine-2-thione (3-MTTT) was the most remarkable one, which may be used as a drug.

Objectives: In vitro genotoxicity of 3-MTTT was investigated using chromosome aberrations (CAs), sister chromatid exchanges (SCEs), micronucleus (MN) and comet assays.

Materials and methods: Various concentrations 0.78, 1.56, 3.13, 6.25, 12.50 and 25.00 μg/mL of 3-MTTT were applied to lymphocytes obtained from two donors for periods of 24 and 48 h. A negative (distilled water), a solvent (2:1 PBS:10% NaOH for cultured lymphocyte, and PBS for isolated lymphocytes) and a positive control (MMC for cultured lymphocytes and H2O2 for isolated lymphocytes) were also maintained.

Results: While this compound did not increase the frequency of abnormal cells and CA/cell ratio compared to negative control (except 48 h, 25 μg/mL), it significantly increased the frequency of SCEs at the four highest concentrations at both treatment periods (except 6.25 μg/mL, 48 h). It significantly decreased the MI in all the concentrations at 24 h (except 0.78 μg/mL) and in the highest three concentrations at 48 h. This compound did not significantly increase the frequency of MN and DNA damage compared to negative control. This compound did not affect the replication and nuclear division index.

Discussion and conclusion: Our results demonstrated that this compound does not represent a significant risk at the genetic level in in vitro human lymphocytes.

Keywords: DNA damage; Tranexamic acid; genotoxicity; lymhocyte culture.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Synthesis of the test substance 3-methyl-5-(4-carboxycyclohexylmethyl)-tetrahydro-2H-1,3,5-thiadiazine-2-thione (Özçelik et al. 2007).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Araldi RP, Melo TCD, Mendes TB, Sa′Ju′nior PL, Nozima BH, Ito ET, Carvalho RFD, Souza EBD, Stocco RDC.. 2015. Using the comet and micronucleus assays genotoxicity studies: a review. Biomed Pharmacother. 72:74–82. - PubMed
    1. Ashfaq M, Aslam A, Mustafa G, Danish M, Faizan Nazar M, Nadeem Asghar M.. 2015. Derivatization/chromophore introduction of anexamic acid and its HPLC determination in pharmaceutical formulations. J Assoc Arab Univ Basic Appl Sci. 17:51–56.
    1. Blasczyk A, Osiecka R, Skolimowski J.. 2003. Induction of chromosome aberrations in cultured human lymphocytes treated with ethoxyquin. Mutat Res. 542:117–128. - PubMed
    1. Bonassi S, El-Zein R, Bolognesi C, Fenech M.. 2010. Micronuclei frequency in peripheral blood lymphocytes and cancer risk: evidence from human studies. Mutagenesis. 26:93–100. - PubMed
    1. Bozkurt G, Abay E, Ates I, Karabogaz G, Ture M, Savran FO, Palanduz S, Temocin K, Algunes C.. 2004. Clastogenicity of selective serotonin-reuptake inhibitors. Mutat Res. 558:137–144. - PubMed

LinkOut - more resources